Esperion Therapeutics, Inc. Provides ETC-1002 Program Update; Reports Fourth Quarter And Full Year 2013 Financial Results
Published: Mar 06, 2014
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provided ETC-1002 development program updates and reported its financial results for the fourth quarter and full year ended Dec. 31, 2013.
Help employers find you! Check out all the jobs and post your resume.